{"name":"TUMOR","title":"","children":[{"id":"breast","name":"breast","presenterLast":"breast","children":[{"id":10832,"name":"breast_10832","title":"The aryl hydrocarbon receptor as driver of cancer immunity","presenterFirst":"David","presenterLast":"Sherr","keywords":"Aryl hydrocarbon receptor;Immunotherapy;Oral Cancer;Cancer immunotherapy","target":"AHR","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":2853,"name":"breast_2853","title":"Therapy-induced senescence associated secretory phenotype enhances breast cancer cell invasion and stemness via CXCR1/2-CXCR1/2 ligands axis","presenterFirst":"Yong Won","presenterLast":"Choi","keywords":"Senescence;Interleukin-8;Breast cancer","target":"CXCR1/2","tumor":"breast","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":3135,"name":"breast_3135","title":"Novel nano-molar small-molecule STAT3 inhibitor series with antitumor activities against human breast cancer","presenterFirst":"Peibin","presenterLast":"Yue","keywords":"STAT3;Small molecule inhibitor;Breast cancer;Antitumor agents","target":"SATA3","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":3537,"name":"breast_3537","title":"Interference of PD-1 and PD-L1 interaction with small-molecule inhibitors enhances the efficacy of tumor-specific CTLs","presenterFirst":"Priscilla","presenterLast":"Redd","keywords":"Cytotoxic T lymphocytes;Small molecule inhibitor;Immunotherapy;PD-L1","target":"PD1/L1","tumor":"breast","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":4571,"name":"breast_4571","title":"EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models","presenterFirst":"Barbara","presenterLast":"Volz","keywords":"Immunomodulation;Tumor microenvironment;T cell","target":"TLR9","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":5324,"name":"breast_5324","title":"Targeting glutamine metabolism enhances tumor specific immunity by inhibiting the generation and function of suppressive myeloid cells","presenterFirst":"Min-Hee","presenterLast":"Oh","keywords":"Tumor microenvironment;Innate immunity;Metastatic tumors;Metabolism","target":"glutamine","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":875,"name":"breast_875","title":"Small-molecule inhibition of cathepsins L and K as potential therapeutics for macrophage-driven breast cancer","presenterFirst":"Samantha","presenterLast":"Dykes","keywords":"Breast cancer;Macrophages;Cathepsin L;Invasion","target":"Cathepsin","tumor":"breast","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"colorectal","name":"colorectal","presenterLast":"colorectal","children":[{"id":10677,"name":"colorectal_10677","title":"Discovery of an imidazopyridine series of potent human IDO1 inhibitors with robust target engagement in a preclinical tumor model","presenterFirst":"Alessia","presenterLast":"Petrocchi","keywords":"Drug discovery;IDO1 inhibitors","target":"IDO1","tumor":"colorectal","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":10771,"name":"colorectal_10771","title":"Promoting an anti-tumor immune environment with a novel, exquisitely selective CSF1R inhibitor","presenterFirst":"Joseph","presenterLast":"Marszalek","keywords":"Macrophages;Drug discovery;CSF1R","target":"CSF1-R","tumor":"colorectal","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":3142,"name":"colorectal_3142","title":"Synergistic immunotherapeutic effects of TLR7/8 agonist on low-dose cyclophosphamide-treated C26 model","presenterFirst":"Lixin","presenterLast":"Li","keywords":"Immunotherapy;Cyclophosphamide;Toll like receptor ligand","target":"TLR7/8","tumor":"colorectal","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":4521,"name":"colorectal_4521","title":"Myeloid-derived suppressor cells potentiate colorectal carcinogenesis: Identification of a novel RIPK3-PGE2 circuit in tumor microenvironment","presenterFirst":"Yongsheng","presenterLast":"Li","keywords":"Gastrointestinal cancers: colorectal;Prostaglandin E2;NF-[kappa]B;Cyclooxygenase","target":"PGE2","tumor":"colorectal","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":4571,"name":"colorectal_4571","title":"EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models","presenterFirst":"Barbara","presenterLast":"Volz","keywords":"Immunomodulation;Tumor microenvironment;T cell","target":"TLR9","tumor":"colorectal","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":7149,"name":"colorectal_7149","title":"High-throughput analysis of MAPK and JAK-STAT signaling in CT26 tumors using a combination of immunophenotyping and phospho-flow cytometry","presenterFirst":"Scott","presenterLast":"Wise","keywords":"Flow cytometry;Phosphorylation;Immunomodulation","target":"MEK","tumor":"colorectal","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"hcc","name":"hcc","presenterLast":"hcc","children":[{"id":3197,"name":"hcc_3197","title":"The biological significance of CCL 16 regulated by thyroid hormone in liver cancer cells","presenterFirst":"Cheng-Heng","presenterLast":"Wu","keywords":"Hepatocellular carcinoma;Chemokines;Macrophages;Thyroid Hormone","target":"CCL16","tumor":"hcc","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"headneck","name":"headneck","presenterLast":"headneck","children":[{"id":10832,"name":"headneck_10832","title":"The aryl hydrocarbon receptor as driver of cancer immunity","presenterFirst":"David","presenterLast":"Sherr","keywords":"Aryl hydrocarbon receptor;Immunotherapy;Oral Cancer;Cancer immunotherapy","target":"AHR","tumor":"headneck","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":3152,"name":"headneck_3152","title":"CXCR7 promotes the migration and invasion of head and neck squamous cell carcinoma through Smad2/Akt signaling","presenterFirst":"Nayoung","presenterLast":"Kim","keywords":"Chemokine receptor;CXCR7;Epithelial-to-mesenchymal transition","target":"CXCR7","tumor":"headneck","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":5329,"name":"headneck_5329","title":"Targeting the kynurenine pathway as a novel metabolic treatment for head and neck cancer","presenterFirst":"Chitra","presenterLast":"Subramanian","keywords":"Head and neck squamous cell carcinoma;IDO1;glycolysis;Kynurenine","target":"IDO1_IDO2_TDO","tumor":"headneck","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":6279,"name":"headneck_6279","title":"Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells","presenterFirst":"Nobuyuki","presenterLast":"Kuribayashi","keywords":"CXCR4;Metastasis;Oral Cancer","target":"CXCR4","tumor":"headneck","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"lung","name":"lung","presenterLast":"lung","children":[{"id":609,"name":"lung_609","title":"Targeting kynurenine pathway for the treatment of cisplatin-resistant lung cancer","presenterFirst":"Medhi","presenterLast":"Wangpaichitr","keywords":"Lung cancer;Cisplatin resistance;Metabolism","target":"IDO1_KYN","tumor":"lung","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":881,"name":"lung_881","title":"Protumoral and pro-metastatic effects of TLR7 in lung cancer","presenterFirst":"Isabelle","presenterLast":"Cremer","keywords":"Tumor microenvironment;TLR7;pro-tumoral;resistance to chemotherapy","target":"TLR7","tumor":"lung","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"lymphoma","name":"lymphoma","presenterLast":"lymphoma","children":[{"id":4571,"name":"lymphoma_4571","title":"EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models","presenterFirst":"Barbara","presenterLast":"Volz","keywords":"Immunomodulation;Tumor microenvironment;T cell","target":"TLR9","tumor":"lymphoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"melanoma","name":"melanoma","presenterLast":"melanoma","children":[{"id":10832,"name":"melanoma_10832","title":"The aryl hydrocarbon receptor as driver of cancer immunity","presenterFirst":"David","presenterLast":"Sherr","keywords":"Aryl hydrocarbon receptor;Immunotherapy;Oral Cancer;Cancer immunotherapy","target":"AHR","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":2758,"name":"melanoma_2758","title":"Targeting autophagy inhibits B16-F10 melanoma growth by enhancing the infiltration of functional NK cells in a CCL5-dependent manner","presenterFirst":"Bassam","presenterLast":"Janji","keywords":"Autophagy;Chemokines;melanoma;Natural killer cells","target":"CCL5","tumor":"melanoma","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":4571,"name":"melanoma_4571","title":"EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models","presenterFirst":"Barbara","presenterLast":"Volz","keywords":"Immunomodulation;Tumor microenvironment;T cell","target":"TLR9","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":7958,"name":"melanoma_7958","title":"A highly potent novel class of SRC-3 inhibitors for the treatment of uveal melanoma","presenterFirst":"Salma","presenterLast":"Kaochar","keywords":"Melanoma/skin cancers;Uveal Melanoma;SRC-3;GNAQ mutant","target":"p160SRC","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"multiple","name":"multiple","presenterLast":"multiple","children":[{"id":10805,"name":"multiple_10805","title":"Phase I dose escalation trial of pegzilarginase in patients with advanced solid tumors","presenterFirst":"Humberto","presenterLast":"Lara-Guerra","keywords":"Arginine deprivation;Solid tumors;pegzilarginase","target":"arginase1","tumor":"multiple","sage":"target-tumor","pharma":"academia","combo":"no","model":"clinical"}]},{"id":"NA","name":"NA","presenterLast":"NA","children":[{"id":2629,"name":"NA_2629","title":"Monitoring CD73 and CD39 ectonucleotidase activities and their modulation by antibodies and small molecules inhibitors","presenterFirst":"Said","presenterLast":"Goueli","keywords":"Cancer marker;Signaling pathways;Hypoxia-inducible genes;Small molecule inhibitor","target":"CD39_CD73","tumor":"NA","sage":"discovery","pharma":"academia","combo":"no","model":"in silico"},{"id":2992,"name":"NA_2992","title":"Rational design of small-molecule immune checkpoints' inhibitors","presenterFirst":"Khaled","presenterLast":"Barakat","keywords":"Cancer;Immunomodulation;Cancer immunotherapy;Immune response","target":"PD1/L1","tumor":"NA","sage":"drug","pharma":"academia","combo":"no","model":"NA"},{"id":5395,"name":"NA_5395","title":"Kit-dependent tissue resident macrophage progenitors drive cancer progression","presenterFirst":"Paulina","presenterLast":"Pathria","keywords":"Macrophages;Inflammation;Kit tyrosine kinase;Stem cells","target":"KIT_SCF","tumor":"NA","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":6738,"name":"NA_6738","title":"Identification and optimization of chemical compounds as potent agonists of human STING with anticancer activity in mice","presenterFirst":"Jian Hui","presenterLast":"Wu","keywords":"Small molecule drugs;STING Agonist;Prostate cancer","target":"STING","tumor":"NA","sage":"drug","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":7627,"name":"NA_7627","title":"The rational design and evaluation of a peptide inhibitor of the PD-1/PD-L1 interaction","presenterFirst":"Rebecca","presenterLast":"Boohaker","keywords":"Immunomodulation;T cell;T lymphocytes;Drug design","target":"PD1/L1","tumor":"NA","sage":"drug","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":9307,"name":"NA_9307","title":"The discovery of novel small molecular CXCR2 antagonist by using ligand-based pharmacophore model","presenterFirst":"Wen-Hai","presenterLast":"Huang","keywords":"Drug discovery;Pharmacophore;CXCR2;antagonists","target":"CXCR2","tumor":"NA","sage":"drug","pharma":"academia","combo":"no","model":"in silico"}]},{"id":"ovarian","name":"ovarian","presenterLast":"ovarian","children":[{"id":1982,"name":"ovarian_1982","title":"Tryptophan catabolism in ovarian cancer","presenterFirst":"Lynelle","presenterLast":"Smith","keywords":"Gynecological cancers: ovarian;Ovarian cancer - serous;Tumor immunity;Immunomodulation","target":"TDO2","tumor":"ovarian","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":7220,"name":"ovarian_7220","title":"Reprogramming of tumor-associated macrophages by a short synthetic peptide eradicates ovarian cancer","presenterFirst":"Reshma","presenterLast":"Bhowmick","keywords":"Macrophages;Gynecological cancers: ovarian;Microenvironment;Innate immunity","target":"PEDF","tumor":"ovarian","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"pancreatic","name":"pancreatic","presenterLast":"pancreatic","children":[{"id":10771,"name":"pancreatic_10771","title":"Promoting an anti-tumor immune environment with a novel, exquisitely selective CSF1R inhibitor","presenterFirst":"Joseph","presenterLast":"Marszalek","keywords":"Macrophages;Drug discovery;CSF1R","target":"CSF1-R","tumor":"pancreatic","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":3049,"name":"pancreatic_3049","title":"CXCR2 signaling in pancreatic cancer induces a tumor supporting inflammatory phenotype of the cancer-associated fibroblasts","presenterFirst":"Mohammad","presenterLast":"Awaji","keywords":"Chemokines;Cancer associated fibroblasts","target":"CXCR2","tumor":"pancreatic","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":3534,"name":"pancreatic_3534","title":"The TLR7/8 agonist R848 induces antitumor responses and attenuates cachexia in a murine model of pancreatic ductal adenocarcinoma","presenterFirst":"Katherine","presenterLast":"Michaelis","keywords":"Cachexia;Immunotherapy;TLR7;Mouse models","target":"TLR7/8","tumor":"pancreatic","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":7868,"name":"pancreatic_7868","title":"Cxcl-12-cxcr4 inhibition enhances immune response in pancreatic ductal adenocarcinoma","presenterFirst":"Bharti","presenterLast":"Garg","keywords":"T cell;Stroma;Cancer;Immune response","target":"CXCL12","tumor":"pancreatic","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"prostate","name":"prostate","presenterLast":"prostate","children":[{"id":3241,"name":"prostate_3241","title":"Preclinical evaluation of the multi tyrosine kinase inhibitor TAS-115 in genetically engineered mouse models of prostate cancer","presenterFirst":"Hirotsugu","presenterLast":"Uemura","keywords":"Kinase inhibitors;Targeted therapy;Prostate cancer;Preclinical testing","target":"CSF1-R","tumor":"prostate","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":5044,"name":"prostate_5044","title":"The CX3CR1-Fractalkine axis drives both circulating prostate cancer cells and macrophages to the bone metastatic microenvironment","presenterFirst":"Ramanpreet","presenterLast":"Kaur","keywords":"Prostate cancer;Microenvironment;Chemokine receptor;Macrophages","target":"CX3CR1","tumor":"prostate","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":5296,"name":"prostate_5296","title":"Obesity and prostate cancer progression: Role of the chemokine CXCL12","presenterFirst":"Songyeon","presenterLast":"Ahn","keywords":"Obesity;Prostate cancer;CXCL12;CXCR4/CXCR7","target":"CXCR4","tumor":"prostate","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]}]}
